Healthcare companies holding on tightly to the Cell Therapy

Uncountable clinical and financial efforts

Where many of the giant pharma, including Novo Nordisk and Takeda, left the cell therapy ground and small biotechs closed their operations, a few players are giving their endless efforts to stretch the modality as long as they can. In the last few months, the volume has witnessed, the stage a peak profile exodus from the cell therapy sector that can exceed. Where Takeda cut the cords of its latest spate of departures, stating that it will stop investments in the modality and unload its platform and pipeline to an as-yet-unaddressed external partner.

This news was out after the Japanese multinational invested millions of dollars for more than 8 years in establishing its cell therapy business. Later, Novo Nordisk also called for the termination of all its cell therapy work involving a type 1 diabetes program. Likewise, the termination, halt and second thought to the cell therapy space hindered the cell therapy treatment sector. The reason could be anything, but there came other players who didn’t give up to serve the best-in-class in this sector.

Impact after the withdrawal of interest for cell therapy

Although there are uncertain events, the excitement regarding cell therapy is still the same and working as an advantage and opportunity for other players who are hanging on to the cell therapy space. BMS is the company to achieve the FDA-approved cell therapies, with the first one to hold two CAR T assets that operate against two different aims. One target is an anti-BCMA product, Abecma, advised for refractory or relapsed multiple myeloma, and another one is the approved drug, Breyanzi (bound to CD19), suitable for various blood cancers.

The pharma’s consistent efforts despite holding the dominant position in the healthcare market to accelerate its CAR T potential are a worthy example in this market. BMS purchased Orbital Therapeutics and its RNA assets pipeline for $1.5 billion. These assets can help reprogram immune cells straight inside the patients’ bodies. The BMS is discovering the utilisation of the CAR Ts for autoimmune diseases, which is mainly crucial for the modality.

Gilead is another inspiring figure in the cell therapy sector. Recently, it sealed its deal with Fierce Biotech to advance in ‘in vivo’ therapies. Gilead is sincerely modernising and shaping its well-known CAR T candidate anitocabtagene autoleucel (anito-cel) in collaboration with California biotech Arcellx.